[The pharmacokinetics of doxorubicin]
Standard
[The pharmacokinetics of doxorubicin]. / Erttmann, Rudolf; Grandt, M; Erb, Norbert; Garbrecht, M; Landbeck, G.
In: KLIN PADIATR, Vol. 198, No. 3, 3, 1986, p. 271-276.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [The pharmacokinetics of doxorubicin]
AU - Erttmann, Rudolf
AU - Grandt, M
AU - Erb, Norbert
AU - Garbrecht, M
AU - Landbeck, G
PY - 1986
Y1 - 1986
N2 - Doxorubicin serum levels were measured with a highly specific reversed-phase HPLC-method in patients undergoing combination chemotherapy. Serum elimination kinetics of doxorubicin follow a bi- or triphasic first order pattern with a high interpatient variability. T 1/2 of the first distribution phase was 5.4 min. T 1/2 of the terminal steady-state elimination phase was 1273 min. After consecutive bolus application of 15 mg/m2 (4 times per 48 h) cumulation of doxorubicin was found in patient's serum. Serum levels 4 h after bolus injection of doxorubicin were found to be correlated with the area under the elimination curve. Therefore, 4 h serum levels after bolus injection can be used for clinical studies correlating pharmacokinetics with antineoplastic properties of doxorubicin.
AB - Doxorubicin serum levels were measured with a highly specific reversed-phase HPLC-method in patients undergoing combination chemotherapy. Serum elimination kinetics of doxorubicin follow a bi- or triphasic first order pattern with a high interpatient variability. T 1/2 of the first distribution phase was 5.4 min. T 1/2 of the terminal steady-state elimination phase was 1273 min. After consecutive bolus application of 15 mg/m2 (4 times per 48 h) cumulation of doxorubicin was found in patient's serum. Serum levels 4 h after bolus injection of doxorubicin were found to be correlated with the area under the elimination curve. Therefore, 4 h serum levels after bolus injection can be used for clinical studies correlating pharmacokinetics with antineoplastic properties of doxorubicin.
M3 - SCORING: Zeitschriftenaufsatz
VL - 198
SP - 271
EP - 276
JO - KLIN PADIATR
JF - KLIN PADIATR
SN - 0300-8630
IS - 3
M1 - 3
ER -